Ovitrelle (Choriogonadotropin Alfa)

Choriogonadotropin alfa, the active ingredient in Ovitrelle, is a gonadotropin hormone presented as a 250 µg/0.5 ml prefilled syringe for subcutaneous injection use. It triggers ovulation and supports luteal phase function in women undergoing assisted reproductive technology cycles. GNH USA supplies Ovitrelle as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ovitrelle as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ovitrelle is a recombinant gonadotropin that acts on the reproductive hormone pathway to induce ovulation. - Controlled ovarian stimulation (COS) cycles: Facilitates final follicular maturation and triggers ovulation in women undergoing IVF or ICSI. - Luteal phase support: Provides hCG activity to sustain the corpus luteum after egg retrieval. - Assisted reproductive technology (ART) cycles: Enhances the timing of embryo transfer by coordinating ovulation. - Ovulation induction for intra‑uterine insemination (IUI) : Improves the likelihood of successful fertilisation.

Adverse reactions to Ovitrelle are generally mild and reversible.

Common Side Effects: - Injection site pain - Headache - Nausea - Fatigue - Mild abdominal discomfort

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS) - Allergic reaction including anaphylaxis - Thromboembolic events - Severe abdominal pain - Ectopic pregnancy

When using Ovar ​   t    g   d  d  ewline

   ewline   ewline   \